Here's What Key Metrics Tell Us About Amneal (AMRX) Q4 Earnings

Amneal Pharmaceuticals (AMRX) reported $730.52 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 18.4%. EPS of $0.12 for the same period compares to $0.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $708.21 million, representing a surprise of +3.15%. The company delivered an EPS surprise of -20.00%, with the consensus EPS estimate being $0.15.While investors scrutinize revenue and earnings changes year-over-year and how they com ...